These results suggest that anlotinib and its combination with aPD-L1 may enhance CD99 signaling between myeloid cells, T cells, and tumor cells, thereby improving immune-mediated tumor destruction and leading to better therapeutic outcomes. Here, CD99 is linked to neoplasm.